The author presents a theory that seeks to comprehensively explain the disease, grounded in extensive scientific evidence. Schizophrenia is characterized by a wide array of symptoms, including positive symptoms (hallucinations and psychosis), negative symptoms (such as catatonia), cognitive impairments, and mood disturbances like depression. These symptoms, though diverse, are unified under the author’s theory by the concept of inflammation-induced stress, which disrupts neural coordination.

The theory proposes that early-life inflammatory stress, possibly due to genetic or epigenetic factors, sets the stage for the disease. Inflammatory stress activates cortisol pathways, releasing molecules that impact neuronal activity. This activation disrupts the synchronized activity of neurons, particularly in the sensory and prefrontal regions of the brain, leading to the hallmark symptoms of schizophrenia.

A crucial component of the theory is the role of chronic stress molecules in disconnecting neurons from one another. Instead of coordinated activity, individual neurons become hyperactive and isolated. For instance, in sensory areas, this causes the perception of hallucinations, as these neurons fire without external stimuli. In motor and cognitive regions, it leads to catatonia and impaired thinking, respectively.

The author also highlights the connection between cannabinoids and schizophrenia, noting that the release of cannabinoids is part of the stress response pathway that becomes dysregulated in the disease. This explains the observed correlation between cannabis use and increased schizophrenia risk, as external cannabis can amplify the already dysregulated system.

The current treatments for schizophrenia primarily address the positive symptoms, such as hallucinations and delusions, using drugs that target serotonin receptors. While these drugs provide some relief, they often fail to address negative symptoms and cognitive impairments. Moreover, their effectiveness varies, and many patients experience significant side effects.

The author suggests a more targeted approach to treatment by focusing on the specific inflammatory molecules and pathways implicated in schizophrenia. Preliminary research supports the feasibility of targeting these pathways, and the author calls for further exploration in this direction. 

Overall, the theory provides a unified explanation of schizophrenia, linking the biochemical disruptions at the neuronal level to the wide range of psychological symptoms. It underscores the need for innovative research to validate these findings and develop targeted therapies. This approach offers hope for improving the lives of individuals living with schizophrenia.